BIO Share Price

Open 24.98 Change Price %
High 25.40 1 Day 5.21 26.06
Low 23.20 1 Week 5.34 26.89
Close 25.20 1 Month 6.56 35.19
Volume 220201 1 Year 8.54 51.26
52 Week High 25.40
52 Week Low 15.44
BIO Important Levels
Resistance 2 27.24
Resistance 1 26.40
Pivot 24.60
Support 1 24.00
Support 2 23.16
ETR Germany Most Active Stocks
CBK 8.54 -1.27%
CBK 8.54 -1.27%
DBK 16.04 -0.74%
DBK 16.04 -0.74%
EOAN 7.30 -0.41%
EOAN 7.30 -0.41%
DTE 16.27 -0.55%
DTE 16.27 -0.55%
DTE 16.27 -0.55%
DTE 16.27 -0.55%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
BIO 25.20 26.06%
BIO 25.20 26.06%
BIO 25.20 26.06%
BIO 25.20 26.06%
BIO 25.20 26.06%
AR4 42.95 22.71%
M3B 1.09 21.11%
R3Q 0.12 20.00%
SMK 0.06 20.00%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
AYO 0.39 -26.42%
DIS 12.76 -16.05%
DIS 12.76 -16.05%
DIS 12.76 -16.05%
DIS 12.76 -16.05%
More..

Biotest AG (ETR: BIO)

BIO Technical Analysis 5
As on 30th Mar 2017 BIO Share Price closed @ 25.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 17.15 & Strong Buy for SHORT-TERM with Stoploss of 18.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO Target for March
1st Target up-side 19.77
2nd Target up-side 20.57
3rd Target up-side 21.36
1st Target down-side 17.51
2nd Target down-side 16.71
3rd Target down-side 15.92
BIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO Address
BIO
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.